The US Food and Drug Administration (FDA) has granted breakthrough therapy desig...
The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the t...
Eli Lilly has announced plans to expand its domestic medicine production in the ...
In this issue: The surge in demand for radiopharmaecuticals, the potential affec...
Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination...
The Phase III trial met the primary and secondary endpoints of reducing tics in ...
With a potential buyer not working out, Idorsia has adjusted an existing partner...
The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar ...
MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 c...
Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (uste...
Mirum Pharmaceuticals’ Ctexli (chenodiol) has gained US Food and Drug Administra...
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m o...
The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence...
Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summ...
Celltrion has secured marketing authorisation from the EC for Avtozma, a biosimi...
PHARMAP 2025 takes place on 14-15 April 2025 in Berlin, Germany.
